Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy

HIV Clinical Trials

Volumn 6, Issue 2, 2005, Pages 92-102

  Hornberger, John ^a,b,c,i   Green, Jesse ^d   Wintfeld, Neil ^d   Cavassini, Matthias ^e   Rockstroh, Jürgen ^f   Giuliani, Giovanni ^g   De Carli, Claudio ^g   Lazzarin, Adriano ^h  

^a Acumen LLC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF BONN   (Germany)

^g ROCHE MILANO RICERCHE   (Italy)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

ⁱ NONE   (United States)

Author keywords

Cost benefit analysis; Enfuvirtide; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENFUVIRTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEATH; DRUG COST; EUROPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; ITALY; LIFE EXPECTANCY; LIFESPAN; LONG TERM CARE; LYMPHOCYTE COUNT; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY;

CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; ITALY; MARKOV CHAINS; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; QUALITY OF LIFE; TREATMENT FAILURE;

EID: 25144449133     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/REJM-TAFW-0A7T-97UA     Document Type: Article

References (46)

1. Egger M, May M, Chêne G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
4. Bozzette SA, Joyce G, McCaffery DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823.
5. Beck EJ, Mandalia S, Williams I, et al. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. AIDS. 1999;13:2157-2164.
6. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy: the ATHENA cohort. AIDS. 2002;16:737-745.
7. Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials. 2002;3:89-98.
8. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-1401.
9. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
10. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302-1307.
11. Lalezari JP, Henry K, O'Hearn M, et al. Efficacy of enfuvirtide plus an optimized background of antiretrovirals in treatment experienced HIV-1 positive patients in North America and Brazil. N Engl J Med. 2003;348:2175-2185.
12. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
13. Katlama C, Arasteh K, Clotet B, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract LB2.
14. Beck JR. Markov models of natural history. J Clin Epidemiol. 1988;41:619-621.
15. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458.
16. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 cell T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201-207.
17. Trottier B, Arasteh K, Henry K, et al. Durability of response of enfuvirtide through 48 weeks in the TORO trials. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract H-835.
18. Cook J, Dasbach E, Coplan P, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial [abstract]. AIDS Res Hum Retrovirus. 1999;15:499-508.
19. L'Informatore Farmaceutico. Milano:OEMF
20. Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 2001;13:733-741.
21. Regione Lombardia. Aggiornamento delle tariffe delle prescrizioni ospedaliere in regime di ricovero. VII:941. 2000.
22. Notizario ISS, anno 2002: vol. 15 n. 10; suppl. 1:COA. 2004.
23. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotyping resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-450.
24. Freedberg KA, Scharfstein JA, Seage GR, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279:130-136.
25. Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res. 1997;6:531-554.
26. Green J, Kleinman L, et al. Subcutaneous Injection Scale: Psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. HIV Clin Trials. 2002;3(5):387-395.
27. Cohen CJ, Clumeck N, Molina J-M, et al. Health-related quality of life with enfuvirtide (ENF; T20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr. 2004;37(1):1140-1146.
28. Cohen C, Hellinger J, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin Trials. 2003;4:347-357.
29. Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS. 2002;16:327-335.
30. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
31. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med. 1998;339:380-386.
32. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
33. Page JB, Lai S, Fletcher MA, et al. Predictors of survival in human immunodeficiency virus type 1-seropositive intravenous drug users. Clin Diagn Lab Immunol. 1996;3:51-60.
34. Perneger TV, Abrahamowicz M, Bartlett G, Yerly S. Time-dependence of survival predictions based on markers of HIV disease. Swiss HIV Cohort Study. J Investig Med. 2000;48:207-212.
35. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29:346-355.
36. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
37. Freedberg KA, Losina E, Weinstein MC, et al. The cost-effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-831.
38. Messori A, Trippoli S, Vaiani M. The cost effectiveness of antiretroviral therapy for HIV disease. N Engl J Med. 2001;345:68.
39. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-52.
40. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunologic changes after stopping effective antiretroviral therapy. AIDS. 1999;13:F79-86.
41. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13:F59-F62.
42. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340:1683-1684.
43. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS. 1999;13:677-683.
44. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999;104:R13-R18.
45. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. JAMA. 2003;288:222-235.
46. Weinstein MC, O'Brien B, Hornberger J, et al. ISPOR Task Force on Good Research Practices-Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9-17.